Session 12: Cardiometabolic benefits of renal, diabetes, and obesity medications: new and breaking literature

Wednesday, September 21, 2022, 12:30 PM - 1:45 PM, Webinar (Online)

AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician (1.00 hours)


Date and Time: Session 10: Wednesday, August 3, 2022 @ 12:30pm-1:45pm PST 
Zoom Webinar ID: 976 0959 8851 
Webinar Link: https://washington.zoom.us/j/97609598851

Talk Title: Cardiometabolic benefits of renal, diabetes, and obesity medications: new and breaking literature

To go back to the main course page, please click here.

1. Discuss the latest literature on CM and renal medications
2. Identify newer indications for CM medications

After registering, learners can access the OnDemand content available following these steps:

• Locate "MyCME" on your screen
• Select "Tests"
• Locate the preferred session of "OT2207 CardioMetabolic ECHO" and click "Pre-Test" to begin. Additional instructions are contained within each session.
• In order to receive a certificate, you must complete the evaluation following the post-test.

Accreditation with Commendation: The University of Washington School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation: The University of Washington School of Medicine designates this other activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

ACPE #: 0130-9999-22-468-H01-P
0130-9999-22-468-L01-P

Christos Argyropoulos MD, PhD, FASN is an Associate Professor with Tenure, the Division Chief of Nephrology at the University of New Mexico Health Sciences Centre (UNM HSC). He is also the Medical Lead for Participant Clinical Interaction unit, that group of research coordinators that executes the NIH trials at UNM’s Clinical and Translational Science Centre and a long-standing member of the School of Medicine and UNM HSC’s Conflict of Interest Committees. He received his medical and doctorate degrees from the University of Patras in Greece. He did his Internship and Residency in Internal Medicine at the University of Cincinnati and trained in Nephrology and Transplant Nephrology at the University of Pittsburgh Medical Centre. As a clinical researcher, he has supervised large observational studies in late phase drug development, clinical epidemiology and large database studies. He is a clinical trialist with over 8 years experience in Phase 3 trials for investigational compounds in chronic kidney disease and diabetes. His research interests evolve around the understanding of the mechanisms of human kidney disease through the development of methods for the analyses of complex biomedical data from molecules to hundreds of thousands of patients. More recently, his research has focused on the discovery of RNA biomarkers for chronic kidney disease associated with diabetes and the development of point of care diagnostics based on portable RNA sequencing devices. While clinically active as a general and transplant Nephrologist, his clinical interest largely concerns the intersection of diabetes with Chronic Kidney Disease. He is the Medical Lead for the Nephrology Clinic at UNM’s Comprehensive Diabetes Care Centre, and the physician supervisor of the clinician pharmacist led clinic for patients with diabetes and kidney disease and transplant recipients. He has been one of the early adopters of the SGLT2 inhibitors which he has heavily promoted since their off label use days in Social Media under the twitter hashtag #flozination. Dr Argyropoulos along with Professor Amy Mottl from UNC have been leading the American Society of Nephrology’s Diabetic Kidney Disease Educational module. He has written numerous editorials about the utilization of SGLT2 inhibitors in clinical practice, and “tweetorials”, connected series of tweets for Medical and Provider education initiatives.

Speaker Disclosure(s): Consultant for Baxter, Otsuka (ended); Consultant for Bayer, Quanta

Planner Disclosure(s):

• Dr. Nicole Ehrhardt, MD is on the Advisory board for Dexcom and Novo Nordisk; Educational Grant: Novo Nordisk and Merck; Investigator: Dexcom
• Dr. Savitha Subramanian, MD is on the advisory board for Abbott Diabetes Care and was formerly on the Advisory board for Akcea Therapeutics and Amarni.
• Laura Montour, MD: none
• Lorena Casas-Wright, MD: none
• Nayan Arora, MD: none

All relevant financial relationships have been mitigated.

Mitigation of Relevant Financial Relationships

University of Washington School of Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Wednesday, September 21, 2022

Novo Nordisk, ECHO Diabetes Action Network (EDAN)